ArticleChemical biology & drug design2026
Curcumin-Loaded GelMA Microspheres Alleviate Osteoarthritis: Transcriptomic Evidence for Immune Microenvironment Remodeling and ECM Homeostasis Restoration.
Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) progression is driven by inflammatory mediators and immune dysregulation within the joint. Curcumin (Cur) possesses multi-target therapeutic potential. However, its clinical application is limited by poor solubility and a short half-life. In this study, we developed injectable Cur-loaded GelMA microspheres (Cur-MS) and evaluated their effects in IL-1β stimulated chondrocytes, cartilage organoids, and a monosodium iodoacetate (MIA) induced rat OA model, complemented by public transcriptomic analysis (GSE114007). The Cur-MS demonstrated uniform size distribution, favorable biocompatibility, and sustained curcumin release. Treatment with Cur-MS significantly reduced chondrocyte apoptosis, reactive oxygen species levels, and hypertrophic markers; restored COL-II and ACAN synthesis; and downregulated MMP13 and inflammatory gene expression. In vivo, Cur-MS improved joint space, alleviated pain, decreased synovial CD68 positive macrophage infiltration and levels of IL-6 and TNF-α, and enhanced chondrogenic gene expression. Public transcriptomic data corroborated these findings, revealing upregulation of MMP13 and downregulation of SOX9 in OA cartilage, consistent with our experimental targets. Collectively, this study provides the first multi-model evidence combined with transcriptomic validation, demonstrating that Cur-MS not only directly protects chondrocytes and restores extracellular matrix homeostasis but also modulates the joint inflammatory immune microenvironment. These findings suggest that Cur-MS represents a promising locally sustained-release therapeutic strategy for OA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.